Skip to main content
Top

Cancer Chemotherapy and Pharmacology

Issue 4/2018

Content (17 Articles)

Review Article

Role of immunotherapy in bladder cancer: past, present and future

Sabeeh-ur-Rehman Butt, Laeeq Malik

Open Access Review Article

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer

Robert D. Morgan, Andrew R. Clamp, D. Gareth R. Evans, Richard J. Edmondson, Gordon C. Jayson

Original Article

Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer

Anthony B. El-Khoueiry, John Sarantopoulos, Cindy L. O’Bryant, Kristen K. Ciombor, Huiping Xu, Melissa O’Gorman, Jayeta Chakrabarti, Tiziana Usari, Bassel F. El-Rayes

Original Article

Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma

Chao Shang, Wei Tang, Chen Pan, Xuanhao Hu, Yang Hong

Original Article

Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153

David Waterhouse, Leora Horn, Craig Reynolds, David Spigel, Jason Chandler, Tarek Mekhail, Mohamed Mohamed, Ben Creelan, Kenneth B. Blankstein, Petros Nikolinakos, Michael J. McCleod, Ang Li, Abderrahim Oukessou, Shruti Agrawal, Nivedita Aanur

Original Article

YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells

Zhi Liu, Zijian Tao, Qing Zhang, Song Wan, Fenglin Zhang, Yan Zhang, Guanyu Wu, Jiandong Wang

Original Article

Electrophilic derivatives of omega-3 fatty acids counteract lung cancer cell growth

Liboria Siena, Chiara Cipollina, Serena Di Vincenzo, Maria Ferraro, Andreina Bruno, Mark Gjomarkaj, Elisabetta Pace

Original Article

Combination of S-1 and gefitinib increases the sensitivity to radiotherapy in lung cancer cells

Jie Cui, Min-Cong Wang, Ya-Min Zhang, Ming-Zhi Ren, Shi-Xiong Wang, Ke-Jun Nan, Li-Ping Song

Original Article

Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors

Frederik Marmé, Carlos Gomez-Roca, Kristina Graudenz, Funan Huang, John Lettieri, Carol Peña, Zuzana Jirakova Trnkova, Jan Eucker

Original Article

FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma

Noboru Nakaigawa, Keiichi Kondo, Tomohiro Kaneta, Ukihide Tateishi, Ryogo Minamimoto, Kazuhiro Namura, Daiki Ueno, Kazuki Kobayashi, Takeshi Kishida, Ichiro Ikeda, Hisashi Hasumi, Kazuhide Makiyama, Narihiko Hayashi, Kimito Osaka, Kentaro Muraoka, Koji Izumi, Takashi Kawahara, Jun-ichi Teranishi, Yasuhide Miyoshi, Yasushi Yumura, Hiroji Uemura, Tomio Inoue, Masahiro Yao

Original Article

Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro

Valentina Citi, Marzia Del Re, Alma Martelli, Vincenzo Calderone, Maria Cristina Breschi, Romano Danesi

Open Access Original Article

Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC)

Takahiro Nakayama, Yasuaki Sagara, Tsutomu Takashima, Nobuki Matsunami, Norikazu Masuda, Yasuo Miyoshi, Tetsuya Taguchi, Toyokazu Aono, Toshikazu Ito, Tatsuo Kagimura, Shinzaburo Noguchi

Open Access Original Article

Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model

Andrea Gruber, Martin Czejka, Philipp Buchner, Marie Kitzmueller, Nairi Kirchbaumer Baroian, Christian Dittrich, Azra Sahmanovic Hrgovcic

Original Article

Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice

Concetta Panebianco, Kaarel Adamberg, Madis Jaagura, Massimiliano Copetti, Andrea Fontana, Signe Adamberg, Kaia Kolk, Raivo Vilu, Angelo Andriulli, Valerio Pazienza

Short Communication

Ibrutinib brain distribution: a preclinical study

Lauriane Goldwirt, Kevin Beccaria, Alain Ple, Hélène Sauvageon, Samia Mourah

Short Communication

A novel way to manage trastuzumab cardiotoxicity

Diaddin Hamdan, François Darrouzain, Theodora Bejan-Angoulvant, Charles Isorni, Laurent Zelek, Gilles Paintaud, Anne Janin, Guilhem Bousquet

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine